

Ayumu Taguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3717467/publications.pdf>

Version: 2024-02-01

55
papers

3,989
citations

126907

33
h-index

161849

54
g-index

56
all docs

56
docs citations

56
times ranked

7477
citing authors

#	ARTICLE	IF	CITATIONS
1	SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. <i>Journal of the National Cancer Institute</i> , 2022, 114, 290-301.	6.3	18
2	Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2543.	3.7	16
3	Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma. <i>Cancer Science</i> , 2021, 112, 1225-1234.	3.9	15
4	Conditional <i>Ror1</i> knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1 α regulator. <i>Cancer Science</i> , 2021, 112, 1614-1623.	3.9	8
5	Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Cancers</i> , 2021, 13, 3642.	3.7	6
6	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , 2020, 159, 2146-2162.e33.	1.3	75
7	Novel urinary protein biomarker panel for early diagnosis of gastric cancer. <i>British Journal of Cancer</i> , 2020, 123, 1656-1664.	6.4	42
8	A Promising CPS1 Inhibitor Keeping Ammonia from Fueling Cancer. <i>Cell Chemical Biology</i> , 2020, 27, 253-254.	5.2	6
9	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 372-379.	6.3	79
10	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414.	27.8	129
11	Harnessing Immune Response to Malignant Lung Nodules. Promise and Challenges. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1184-1186.	5.6	0
12	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. <i>Nature Communications</i> , 2019, 10, 254.	12.8	120
13	HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D. <i>Journal of Infectious Diseases</i> , 2018, 217, 413-417.	4.0	8
14	Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. <i>JAMA Oncology</i> , 2018, 4, e182078.	7.1	109
15	A Statistical Method for Detecting Differentially Expressed SNVs Based on Next-Generation RNA-Seq Data. <i>Biometrics</i> , 2017, 73, 42-51.	1.4	2
16	Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw231.	6.3	69
17	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw266.	6.3	116
18	MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. <i>Cancer Research</i> , 2017, 77, 4414-4425.	0.9	85

#	ARTICLE	IF	CITATIONS
19	Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 573.	4.1	130
20	Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 95466-95480.	1.8	60
21	Switching Roles of TGF- β 2 in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. <i>Journal of Clinical Medicine</i> , 2016, 5, 109.	2.4	30
22	Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 317-323.	1.5	15
23	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. <i>Molecular Cell</i> , 2016, 61, 520-534.	9.7	142
24	Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1555-64.	7.1	174
25	Deciphering the complexity of the cancer proteome for diagnostic applications. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 399-405.	3.1	5
26	Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. <i>Metabolites</i> , 2015, 5, 192-210.	2.9	69
27	Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival. <i>Cancer Research</i> , 2015, 75, 1789-1800.	0.9	179
28	Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	72
29	MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. <i>Cancer Prevention Research</i> , 2015, 8, 1112-1119.	1.5	25
30	Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. <i>Journal of Clinical Oncology</i> , 2015, 33, 3880-3886.	1.6	88
31	Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. <i>Proteomics</i> , 2014, 14, 2750-2759.	2.2	20
32	Mouse to Human Blood-Based Cancer Biomarker Discovery Strategies. <i>Cold Spring Harbor Protocols</i> , 2014, 2014, pdb.top078808.	0.3	5
33	A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets. <i>Cancer Research</i> , 2014, 74, 4694-4705.	0.9	40
34	Unleashing the Power of Proteomics to Develop Blood-Based Cancer Markers. <i>Clinical Chemistry</i> , 2013, 59, 119-126.	3.2	52
35	Circulating Pro-Surfactant Protein B as a Risk Biomarker for Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1756-1761.	2.5	24
36	Pro-Surfactant Protein B As a Biomarker for Lung Cancer Prediction. <i>Journal of Clinical Oncology</i> , 2013, 31, 4536-4543.	1.6	73

#	ARTICLE	IF	CITATIONS
37	Enrichment strategies in glycomics-based lung cancer biomarker development. <i>Proteomics - Clinical Applications</i> , 2013, 7, 664-676.	1.6	34
38	CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1378-1388.	1.1	71
39	miR-375 Is Activated by ASH1 and Inhibits YAP1 in a Lineage-Dependent Manner in Lung Cancer. <i>Cancer Research</i> , 2011, 71, 6165-6173.	0.9	124
40	Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications. <i>Nature Protocols</i> , 2011, 6, 253-269.	12.0	41
41	Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models. <i>Cancer Cell</i> , 2011, 20, 289-299.	16.8	158
42	Application of Proteomics to Cancer Early Detection. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 423-428.	2.0	47
43	The grand challenge to decipher the cancer proteome. <i>Nature Reviews Cancer</i> , 2010, 10, 652-660.	28.4	117
44	Small-bowel obstruction: diagnostic comparison between double-balloon endoscopy and fluoroscopic enteroclysis, and the outcome of enteroscopic treatment. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 84-93.	1.0	79
45	Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11.2 in human lung cancer. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 810-818.	2.8	81
46	Identification of Hypoxia-Inducible Factor-1 as a Novel Target for miR-17-92 MicroRNA Cluster. <i>Cancer Research</i> , 2008, 68, 5540-5545.	0.9	290
47	Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1. <i>Cancer Research</i> , 2007, 67, 6007-6011.	0.9	200
48	Rugal hyperplastic gastritis increases the risk of gastric carcinoma, especially diffuse and p53-independent subtypes. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 561-566.	1.6	5
49	MDM2 Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor Prognosis. <i>Journal of Clinical Oncology</i> , 2006, 24, 4434-4440.	1.6	122
50	Severity of atrophic gastritis related to antiparietal cell antibody and gastric carcinogenesis, including p53 mutations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 545-551.	2.8	7
51	Interleukin-8 gene polymorphism associated with susceptibility to non-cardia gastric carcinoma with microsatellite instability. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1129-1135.	2.8	32
52	Interleukin-8 Promoter Polymorphism Increases the Risk of Atrophic Gastritis and Gastric Cancer in Japan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2487-2493.	2.5	235
53	Endoscopic resection of Peutz-Jeghers polyps throughout the small intestine at double-balloon enteroscopy without laparotomy. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 140-147.	1.0	178
54	The association between tumour necrosis factor-1 gene polymorphism and the susceptibility to rugal hyperplastic gastritis and gastric carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 693-700.	1.6	30

#	ARTICLE	IF	CITATIONS
55	Cancer proteomics. , 0, , 52-57.		0